Replies to post #1353 on BioLineRx Ltd (BLRX)

[shub]

Thanks again Midas; it's a rather compelling argument, if redundant.
Not mentioned is the long wait till possible FDA approval, the high failure rate of promising onco drug candidates, and the unfortunate fact that our 39 million fades to insignificance in the face of the cost of Phase 3 trials.
That said, it's under a buck just now and i think i'll gamble on a few more shares while it's so cheap...grin.